SCARA5 and neoplasm: Targeting of tumor cells has been achieved through the known ability of APO to recognize the receptors: TfR1 and SCARA5, which are overexpressed in rapidly proliferating cells, such as cancer cells [19,36], and through the recognition of FR receptors by the folate moiety attached to the APO nanocarriers.